University of Southern Denmark

Overview:
The University of Southern Denmark welcomed the first students onto the campus in Odense in September 1966, and things have been developing by leaps and bounds ever since. SDU now have five faculties with more than 32,000 students, almost 20% of whom are from abroad, and more than 4,000 employees distributed across our main campus in Odense and regional campuses in Slagelse, Kolding, Esbjerg and Sønderborg.
SDU conducts world-class research and are one of the top fifty young universities in the world. Every day more than 2,000 researchers and 32,000 students build on the university’s reputation as a centre of academic excellence.
Research:
The University of Southern Denmark consists of five faculties:
<ul>
<li>Faculty of Engineering</li>
<li>Faculty of Health Sciences</li>
<li>Faculty of Science</li>
<li>Faculty of Business and Social Sciences</li>
<li>Faculty of Humanities</li>
</ul>
Every faculty consists of several departments, where the departments have a noticeable academic and economic independence and responsibility. Together departments and centres cover a wide range of research fields and educational opportunities.
Industry Partnerships:
SDU works purposefully to create dialogue between the university’s researchers and the surrounding society. To promote and make communication and knowledge exchange visible, faculties cooperate with various external parties. These activities are organised in centres. The centres serve to promote special purposes in research, education or knowledge exchange.
SDU RIO (SDU Research &amp; Innovation Organisation) supports collaboration between research, education, the business community and the public sector.

<h1 id="technology-overview">Technology Overview</h1>
SDU offer a novel approach to target Glioblastoma Multiforme (GBM). No effective therapy exists for GBM, the most frequent and aggressive brain cancer. Reasons for this are pronounced tumor heterogeneity, and the fact that radiation and chemotherapy, due to side-effects cannot be given in doses large enough to eradicate all tumor cells. Instead SDU researchers target cell division, a common event in all GBM cells, using Auger-electron emitter irradiation, the range of which is less than a cell diameter, which means little or no side-effects. By convection-enhanced delivery (CED) of 125Iodine-UdR, the researchers bypass the blood-brain barrier. This intra-tumoral therapy is combined with systemic chemotherapy.
<img src="https://s3-eu-west-1.amazonaws.com/assets.in-part.com/figures/L02UxCeCQk6LD7ZwqEy8_glio1.png" alt="Figure 2: Proof of Concept" />
<img src="https://s3-eu-west-1.amazonaws.com/assets.in-part.com/figures/JW1MVIQPR2GyVyaxu6IN_glio2.png" alt="Figure 3: Stage of development" />
<h1 id="opportunity">Opportunity</h1>
SDU offer development of a potential new compound with established Proof of Concept in rats implanted with human glioblastoma tumor cells. The market potential is above $ 1 billion. SDU are looking to raise initially $ 9.5 million in order to obtain first data in patients with an initial close of $ 2.8 million, to complete the pre-clinical program to mature and validate the compound and expand the IPR.